Central serous chorioretinopathy (CSC) is a leading cause of permanent vision loss, ranking fourth among macular diseases, trailing only age-related macular degeneration, diabetic retinopathy, and retinal vein obstruction. While mounting evidence implicates inflammation as a pivotal factor in the onset and advancement of CSC, the specific pathophysiological process and molecular mechanisms underlying inflammation remain incompletely understood. A complex network of cytokines, chemokines, and adhesion molecules interplay to trigger inflammatory and pathological cascades, highlighting the need for a comprehensive comprehension of the inflammation-related mechanisms behind CSC progression. In this piece, we examine the existing comprehension of CSC's pathology and pathogenesis. Additionally, we present an overview of the mechanisms underlying the onset and progression of CSC inflammation, followed by a thorough analysis and discussion of the potential of targeted inflammatory intervention for both preventing and treating CSC.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11148560 | PMC |
http://dx.doi.org/10.3389/fphar.2024.1200492 | DOI Listing |
Photodiagnosis Photodyn Ther
January 2025
Istanbul Medeniyet University, Faculty of Medicine, Department of Ophthalmology, Istanbul, Turkey. Electronic address:
Objective: Imaging techniques have demonstrated changes in the choroid and retina in acute central serous chorioretinopathy (CSCR), but the effects on the optic nerve head (ONH) remain unclear. This study investigates ONH structural changes in acute CSCR using enhanced deep imaging optic coherence tomography (EDI-OCT).
Methods: A prospective cohort study included 51 acute CSCR patients and 51 healthy controls aged 18-65 years.
J Fr Ophtalmol
January 2025
Department of Ophthalmology, Saarland University Medical Center UKS, Homburg/Saar, Germany.
Purpose: To investigate the morphologic and functional outcomes of nanosecond subthreshold (ST) laser treatment for patients with chronic central serous chorioretinopathy (CSC).
Methods: In this prospective study, 44 patients were treated with the ST nanosecond laser with a follow-up period of 12 months. All target variables were measured at 1, 3, 6 and 12 months after the first laser treatment.
Retina
December 2024
Retinal Disorders and Ophthalmic Genetics Division, Stein Eye Institute, University of California Los Angeles, Los Angeles, CA, United State.
BMJ Case Rep
January 2025
Ophthalmology, JIPMER, Puducherry, India.
Central serous chorioretinopathy (CSC) is a known side effect of systemic steroid therapy. The role of intravitreal steroids in causing CSC is controversial. We present two cases of acute CSC that developed after intravitreal steroid injections.
View Article and Find Full Text PDFBiomedicines
December 2024
Tel Aviv Medical Center, Department of Ophthalmology, Tel Aviv University, Tel Aviv 6423906, Israel.
Background/objectives: To evaluate the impact of intravitreal bevacizumab (IVB) therapy on anatomical and visual outcomes in patients with macular neovascularization (MNV) secondary to chronic central serous chorioretinopathy (cCSC).
Methods: This retrospective observational study reviewed the medical records of treatment-naïve patients diagnosed with cCSC complicated by MNV and treated with IVB injections over a 5-year period. The presence of MNV was confirmed using optical coherence tomography angiography (OCTA).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!